FY2026 EPS Forecast for electroCore Boosted by Analyst

Key Points

• Brookline Capital Markets raised its FY2026 EPS forecast for electroCore to a loss of $1.25 per share from $1.39, close to the consensus loss estimate of $1.22.
• In its latest quarter, electroCore reported a loss of $0.13 per share, beating the $0.27 consensus loss, while revenue of $9.69 million fell short of the $10.93 million estimate.
• Analyst sentiment is mixed: the stock has a consensus Hold rating and an $18 price target, with one Buy, one Hold, and one Sell rating.

electroCore, Inc. (NASDAQ:ECOR - Free Report) - Equities researchers at Brookline Capital Markets boosted their FY2026 earnings estimates for shares of electroCore in a research report issued on Thursday, November 5th. Brookline Capital Markets analyst F. Ahmed now forecasts that the company will earn ($1.25) per share for the year, up from their prior estimate of ($1.39). The consensus estimate for electroCore's current full-year earnings is ($1.22) per share. Brookline Capital Markets also issued estimates for electroCore's Q4 2026 earnings at ($0.23) EPS.

electroCore (NASDAQ:ECOR - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.14. The firm had revenue of $9.69 million during the quarter, compared to the consensus estimate of $10.93 million.

Separately, Weiss Ratings reiterated a "sell (d-)" rating on shares of electroCore in a research note on Monday, September 21st. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, electroCore presently has a consensus rating of "Hold" and a consensus price target of $18.00.

electroCore Price Performance

NASDAQ ECOR opened at $7.18 on Tuesday. The business has a fifty day moving average price of $9.23 and a two-hundred day moving average price of $7.76. electroCore has a fifty-two week low of $4.41 and a fifty-two week high of $12.70. The stock has a market capitalization of $64.76 million, a PE ratio of -5.17 and a beta of 1.23.

Insider Activity at electroCore

In related news, CFO Joshua Lev sold 3,000 shares of the company's stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $9.36, for a total transaction of $28,080.00. Following the completion of the transaction, the chief financial officer directly owned 84,889 shares in the company, valued at $794,561.04. This represents a 3.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Thomas J. Errico acquired 5,000 shares of the company's stock in a transaction that occurred on Monday, September 14th. The stock was bought at an average cost of $9.82 per share, with a total value of $49,100.00. Following the purchase, the director owned 363,904 shares in the company, valued at $3,573,537.28. The trade was a 1.39% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have sold a total of 20,000 shares of company stock worth $200,120 over the last ninety days. 7.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On electroCore

A hedge fund recently bought a new stake in electroCore stock. WealthShield Partners LLC bought a new stake in electroCore, Inc. (NASDAQ:ECOR - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 25,978 shares of the company's stock, valued at approximately $157,000. WealthShield Partners LLC owned about 0.32% of electroCore at the end of the most recent quarter. Institutional investors and hedge funds own 26.74% of the company's stock.

About electroCore

electroCore, Inc NASDAQ: ECOR is a commercial-stage medical device company focused on bioelectronic medicine and non-invasive vagus nerve stimulation (nVNS). Its technology is designed to stimulate the vagus nerve through the neck without requiring surgery or implanted components.

The company's primary prescription product is gammaCore, a handheld nVNS device used for the acute treatment of pain associated with migraine and episodic cluster headaches in adults. electroCore also markets consumer-oriented products, including Truvaga, a handheld vagus nerve stimulation device positioned for general wellness applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.